References
- Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703–718.
- Hamby JM, Showalter HD. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:169–193.
- Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol 2009;78:1083–1094.
- Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178–182.
- Garofalo A, Goossens L, Baldeyrou B, Lemoine A, Ravez S, Six P et al. Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives. J Med Chem 2010;53:8089–8103.
- Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY et al. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs 2008;19:777–782.
- Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Anticancer and antiviral sulfonamides. Curr Med Chem 2003;10:925–953.
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
- Neri D, Supuran CT.Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–777.
- Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999;42:3789–3799.
- Van Kesteren C, Beijnen JH, Schellens JH. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 2002;13:989–997.
- Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT. Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009;52:2226–2232.
- Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009;92:423–428.
- Gitto R, Agnello S, Ferro S, De Luca L, Vullo D, Brynda J et al. Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme–ligand X-ray studies. J Med Chem 2010;53:2401–2408.
- Huang Z, Lin Z, Huang J. A novel kind of antitumour drugs using sulfonamide as parent compound. Eur J Med Chem 2001;36:863–872.
- Alafeefy AM, Kadi AA, Al-Deeb OA, El-Tahir KE, Al-Jaber NA. Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives. Eur J Med Chem 2010;45:4947–4952.
- Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–1112.